Zobrazeno 1 - 10
of 388
pro vyhledávání: '"Udai, Banerji"'
Autor:
Mary Van Zyl, Anne Barell, Bridget Cooley, Janet Hanwell, Josie Parlak, Udai Banerji, Johann De Bono, Adam Sharp, Juanita Lopez, Nicolo Matteo Luca Battisti, Anna Minchom
Publikováno v:
Cancer Reports, Vol 7, Iss 6, Pp n/a-n/a (2024)
Abstract Background Though cancer is more prevalent in the older population, this patient group are underrepresented in phase I oncology trials. Aims We evaluated the use of a geriatric screening tool (SAOP3) in patients of 70 years of age or older w
Externí odkaz:
https://doaj.org/article/898ed05cc677458a94115355b7e29a02
Autor:
James Spicer, Bristi Basu, Ana Montes, Udai Banerji, Rebecca Kristeleit, Rowan Miller, Gareth J. Veal, Christopher J. Corrigan, Stephen J. Till, Mariangela Figini, Silvana Canevari, Claire Barton, Paul Jones, Sarah Mellor, Simon Carroll, Chris Selkirk, George Nintos, Vineet Kwatra, Ionut-Gabriel Funingana, Gary Doherty, Hannah J. Gould, Giulia Pellizzari, Mano Nakamura, Kristina M. Ilieva, Atousa Khiabany, Chara Stavraka, Jitesh Chauhan, Cheryl Gillett, Sarah Pinder, Heather J. Bax, Debra H. Josephs, Sophia N. Karagiannis
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-11 (2023)
Abstract All antibodies approved for cancer therapy are monoclonal IgGs but the biology of IgE, supported by comparative preclinical data, offers the potential for enhanced effector cell potency. Here we report a Phase I dose escalation trial (NCT025
Externí odkaz:
https://doaj.org/article/10c6fe5134614037a52da348794ee12d
Autor:
Crescens Tiu, Rajiv Shinde, Abhijit Pal, Andrea Biondo, Alex Lee, Nina Tunariu, Shaman Jhanji, Vimal Grover, Kate Tatham, Pascale Gruber, Udai Banerji, Johann S. De Bono, Emma Nicholson, Anna R. Minchom, Juanita S. Lopez
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Pp 189-195 (2021)
Introduction: Immune checkpoint inhibitors (ICIs) are increasingly a standard of care for many cancers; these agents can result in immune-related adverse events (irAEs) including fever, which is common but can rarely be associated with systemic immun
Externí odkaz:
https://doaj.org/article/795643acaadb42b992e7de8af283b261
Autor:
Robert Brown, Christina Yap, Johann De Bono, Malaka Ameratunga, Anna Minchom, Wei Yuan, Mateus Crespo, Bora Gurel, Ines Figueiredo, Susana Miranda, Ruth Riisnaes, Ana Ferreira, Claudia Bertan, Rita Pereira, Chloe Baker, Nina Tunariu, Suzanne Carreira, Udai Banerji, Juanita Lopez, Alison Turner, Wentin Chen, Abhijit Pal, Dionysis Papadatos-Pastos, Toby Prout, Maxime Chénard-Poirier, Andra Curcean, Nahal Masrour, Ricardo Morilla, Ben Jenkins, Anna Zachariou, Mona Parmar
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 6 (2022)
Externí odkaz:
https://doaj.org/article/b9a84246b2264ed1b2c2acbbf2f19d79
Autor:
Lillian M. Smyth, Gerald Batist, Funda Meric-Bernstam, Peter Kabos, Iben Spanggaard, Ana Lluch, Komal Jhaveri, Andrea Varga, Andrea Wong, Alison M. Schram, Helen Ambrose, T. Hedley Carr, Elza C. de Bruin, Carolina Salinas-Souza, Andrew Foxley, Joana Hauser, Justin P. O. Lindemann, Rhiannon Maudsley, Robert McEwen, Michele Moschetta, Myria Nikolaou, Gaia Schiavon, Pedram Razavi, Udai Banerji, José Baselga, David M. Hyman, Sarat Chandarlapaty
Publikováno v:
npj Breast Cancer, Vol 7, Iss 1, Pp 1-7 (2021)
Abstract Five to ten percent of ER+ metastatic breast cancer (MBC) tumors harbor somatic PTEN mutations. Loss of function of this tumor-suppressor gene defines a highly aggressive, treatment-refractory disease for which new therapies are urgently nee
Externí odkaz:
https://doaj.org/article/97cb292e26054c75a968bad21fc37c9b
Autor:
Dearbhaile Catherine Collins, Raghav Sundar, Anastasia Constantidinou, David Dolling, Timothy Anthony Yap, Sanjay Popat, Mary E. O’Brien, Udai Banerji, Johann Sebastian de Bono, Juanita Suzanne Lopez, Nina Tunariu, Anna Minchom
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-7 (2020)
Abstract Background Malignant pleural mesothelioma (MPM) is traditionally characterized by local destructive spread of the pleura and surrounding tissues. Patient outcomes in MPM with distant metastatic dissemination are lacking. Methods In this retr
Externí odkaz:
https://doaj.org/article/6b23bc4f4e8a4cf988b9ae59f8ab79b6
Autor:
Ahmet Acar, Daniel Nichol, Javier Fernandez-Mateos, George D. Cresswell, Iros Barozzi, Sung Pil Hong, Nicholas Trahearn, Inmaculada Spiteri, Mark Stubbs, Rosemary Burke, Adam Stewart, Giulio Caravagna, Benjamin Werner, Georgios Vlachogiannis, Carlo C. Maley, Luca Magnani, Nicola Valeri, Udai Banerji, Andrea Sottoriva
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-14 (2020)
Evolutionary steering uses therapies to control tumour evolution by exploiting trade-offs. Here, using a barcoding approach applied to large cell populations, the authors explore evolutionary steering in lung cancer cells treated with EGFR inhibitors
Externí odkaz:
https://doaj.org/article/7266ff52e4984f1da8cfe86c3ba11937
Autor:
Christina Yap, Deme Karikios, Johann De Bono, Anna Minchom, Udai Banerji, Juanita Lopez, Sarah Stapleton, Frances Boyle, Abhijit Pal, Julia Lai-Kwon, Robert Daly, Dimitrios Magkos, Bindumalini Rao Baikady
Publikováno v:
BMJ Open, Vol 11, Iss 9 (2021)
Introduction Early phase cancer clinical trials have become increasingly complicated in terms of patient selection and trial procedures—this is reflected in the increasing length of participant information sheets (PIS). Informed consent for early p
Externí odkaz:
https://doaj.org/article/b5e4da0c65834b85bca76b00cf5340d0
Autor:
Andrea Biondo, Abhijit Pal, Ruth Riisnaes, Rajiv Shinde, Crescens Tiu, Fran Lockie, Chloe Baker, Claudia Bertan, Mateus Crespo, Ana Ferreira, Rita Pereira, Ines Figueiredo, Susana Miranda, Bora Gurel, Suzanne Carreira, Udai Banerji, Johann de Bono, Juanita Lopez, Nina Tunariu, Anna Minchom
Publikováno v:
Cancer Treatment and Research Communications, Vol 27, Iss , Pp 100309- (2021)
ABSTRACT: Early-phase cancer clinical trials are becoming increasingly accessible for patients with advanced cancer who have exhausted standard treatment options and later phase trial options. Many of these trials mandate research tissue biopsies. Re
Externí odkaz:
https://doaj.org/article/7ee213af1fdd4bdb8f1be7e81291035f
Autor:
Sarah Halford, Gareth J. Veal, Stephen R. Wedge, Geoffrey S. Payne, Chris M. Bacon, Philip Sloan, Ilaria Dragoni, Kathrin Heinzmann, Sarah Potter, Becky M. Salisbury, Maxime Chénard-Poirier, Alastair Greystoke, Elizabeth C. Howell, William A. Innes, Karen Morris, Chris Plummer, Mihaela Rata, George Petrides, Hector C. Keun, Udai Banerji, Ruth Plummer
Publikováno v:
Clin Cancer Res
Purpose: Inhibition of monocarboxylate transporter (MCT) 1–mediated lactate transport may have cytostatic and/or cytotoxic effects on tumor cells. We report results from the dose-escalation part of a first-in-human trial of AZD3965, a first-in-clas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f46578631c1f8cdcae05d3e1c1e8c2c2
https://doi.org/10.1158/1078-0432.ccr-22-2263
https://doi.org/10.1158/1078-0432.ccr-22-2263